BAYER AG
π©πͺGermany
- Country
- π©πͺGermany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Moxifloxacin Versus Amoxicillin Clavulanic Acid in Treatment of Acute Exacerbation of Chronic Bronchitis
Phase 4
Completed
- Conditions
- Chronic Bronchitis
- Interventions
- First Posted Date
- 2008-04-11
- Last Posted Date
- 2014-12-01
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1372
- Registration Number
- NCT00656747
Placebo-controlled Study Evaluating the Efficacy and Safety of Vardenafil in Subjects With Erectile Dysfunction
Phase 2
Completed
- Conditions
- Erectile Dysfunction
- Interventions
- Drug: PlaceboDrug: Levitra (Vardenafil, BAY38-9456)
- First Posted Date
- 2008-04-10
- Last Posted Date
- 2013-10-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 463
- Registration Number
- NCT00656188
Assess the Effect of Daily Treatment of Vardenafil 20mg or Sildenafil 100mg and Placebo on Sperm Function
Phase 4
Completed
- Conditions
- Erectile Dysfunction
- Interventions
- First Posted Date
- 2008-04-10
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 200
- Registration Number
- NCT00655590
Vardenafil Orodispersible Tablet (ODT) Versus Placebo in Males With Erectile Dysfunction, 50% of Whom Are to be 65 Years or Older.
Phase 3
Completed
- Conditions
- Erectile Dysfunction
- Interventions
- Drug: PlaceboDrug: Vardenafil ODT (STAXYN, BAY38-9456)
- First Posted Date
- 2008-04-10
- Last Posted Date
- 2014-08-01
- Lead Sponsor
- Bayer
- Target Recruit Count
- 339
- Registration Number
- NCT00655629
- Locations
- π¦πΊ
Berry Road Medical Centre, St Leonards, New South Wales, Australia
πΊπΈSynergy Clinical Research Center, National City, California, United States
π¦πΊSydney Men's Health, Bondi Junction, New South Wales, Australia
A Study to Assess the Efficacy and Safety of Vardenafil in the Treatment of Male Patients With Erectile Dysfunction
- First Posted Date
- 2008-04-09
- Last Posted Date
- 2014-12-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 527
- Registration Number
- NCT00654914
Evaluating the Efficacy and Safety of Vardenafil in Patients Erectile Dysfunction Solely Secondary to Spinal Cord Injury
Phase 3
Completed
- Conditions
- Erectile Dysfunction
- Interventions
- Drug: Vardenafil (Levitra, BAY38-9456)Drug: Placebo
- First Posted Date
- 2008-04-09
- Last Posted Date
- 2013-09-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 418
- Registration Number
- NCT00654680
Cycle Control and Safety of E2-DRSP
Phase 2
Completed
- Conditions
- Contraceptive, Oral, Hormonal
- Interventions
- Drug: E2/DRSP (BAY 86-4891) dose 1 (SH T04984E)Drug: DRSP (ZK 30595) dose 1 (SH T04984F)Drug: E2/DRSP (BAY 86-4891) dose 2 (80458739)Drug: E2/DRSP (BAY 86-4891) dose 4 (80458720)Drug: PlaceboDrug: E2/DRSP (BAY 86-4891) dose 3 (80458755)Drug: E2/DRSP (BAY 86-4891) dose 5 (80458712)Drug: DRSP (ZK 30595) dose 2 (80458690)
- First Posted Date
- 2008-04-07
- Last Posted Date
- 2015-04-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 635
- Registration Number
- NCT00653614
Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Magnetic Resonance Angiography
Phase 2
Completed
- Conditions
- Magnetic Resonance AngiographyPeripheral Vascular DiseasesPeripheral Arterial Diseases
- Interventions
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2013-10-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 12
- Registration Number
- NCT00652418
Investigate Impact of Yasmin vs Microgynon on Hemostasis Parameters in Healthy Women
Phase 4
Completed
- Conditions
- Healthy
- Interventions
- Drug: Yasmin (DRSP 3mg/EE 0.03 mg)Drug: Microgynon (LNG 0.15 mg/EE 0.03 mg)
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 43
- Registration Number
- NCT00651846
BAY38-9456 - Supportive Trial for Spinal Injury
Phase 3
Completed
- Conditions
- Spinal Cord InjuryErectile DysfunctionSexual Dysfunction
- Interventions
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2014-12-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 32
- Registration Number
- NCT00652262
Β© Copyright 2025. All Rights Reserved by MedPath